Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Rapport Therapeutics, Inc. Common Stock
No splits on record
Nothing in RAPP's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Revenue | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $15K |
| Gross Profit | $0 | $0 | $0 | -$15K |
| Gross Margin | - | - | - | - |
| Research and Development | $94.79M | $60.94M | $28M | $9.12M |
| Selling, General, and Administrative | $30.31M | $22.12M | $8.18M | $1.37M |
| Other | $0 | $0 | $0 | -$129K |
| Total Operating Expenses | $125.1M | $83.06M | $36.18M | $10.35M |
| Operating Income (EBIT) | -$125.1M | -$83.06M | -$36.18M | -$10.37M |
| Operating Margin | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $285K |
| Interest Income | $13.62M | $12.14M | $2.53M | $0 |
| Other Income (Expense) | $13.62M | $4.75M | $1.4M | -$285K |
| Income Before Tax (EBT) | -$111.48M | -$78.31M | -$34.78M | -$10.65M |
| Income Tax Expense | $0 | $0 | $10K | $0 |
| Net Income | -$111.48M | -$78.31M | -$34.79M | -$10.65M |
| Net Income Margin | - | - | - | - |
| Supplementary Data | ||||
| EPS | -2.86 | -3.78 | -0.95 | -0.29 |
| Diluted EPS | -2.86 | -3.78 | -0.95 | -0.29 |
| Weighted Average OS | 46.98M | 20.74M | 18.08M | 20.12M |
| EBITDA | -$124.08M | -$82.22M | -$36.07M | -$10.35M |
| EBITDA Margin | - | - | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Assets | ||||
| Current Assets | ||||
| Cash and Cash Equivalents | $52.65M | $56.8M | $70.17M | $31.16M |
| Short-Term Investments | $437.89M | $248.47M | $77.31M | $0 |
| Cash and Short-Term Investments | $490.54M | $305.28M | $147.48M | $31.16M |
| Accounts Receivable | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Current Assets | $8.02M | $4.52M | $3.39M | $0 |
| Total Current Assets | $498.56M | $309.8M | $150.87M | $31.27M |
| Long-Term Assets | ||||
| Property, Plant & Equipment Net | $12.88M | $4.97M | $4M | $335K |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $985K | $160K | $551K | $0 |
| Total Long-Term Assets | $13.87M | $5.13M | $4.55M | $335K |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $512.43M | $314.93M | $155.42M | $31.6M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | $4.19M | $1.95M | $2.5M | $1.45M |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $7.12M | $3.71M | $2.41M | $0 |
| Total Current Liabilities | $19.05M | $8.77M | $8.8M | $1.66M |
| Long-Term Liabilities | ||||
| Long-Term Debt | $8.73M | $0 | $0 | $10.44M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $170.78M | $0 |
| Total Long-Term Liabilities | $8.73M | $739K | $172.25M | $10.44M |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $27.78M | $9.51M | $181.06M | $12.1M |
| Stockholders' Equity | ||||
| Preferred Stock | $0 | $0 | $0 | $29.57M |
| Common Stock | $48K | $37K | $4K | $31K |
| Retained Earnings | -$235.23M | -$123.75M | -$45.44M | -$10.65M |
| Comprehensive Income & Other | $546K | -$522K | $4K | $0 |
| Other Stockholders' Equity | $719.83M | $429.13M | $19.8M | $30.13M |
| Total Equity | $484.65M | $305.43M | -$25.63M | $19.5M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $512.43M | $314.93M | $155.42M | $31.6M |
| Supplementary Data | ||||
| Total Debt | $11.48M | $1.48M | $2.15M | $10.44M |
| Net Debt | -$41.16M | -$55.33M | -$68.02M | -$20.72M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Operating Activities | ||||
| Net Income | -$111.48M | -$78.31M | -$34.79M | -$10.65M |
| Depreciation & Amortization | $1.02M | $839K | $112K | $15K |
| Deferred Income Tax | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $18.86M | $10.23M | $3.52M | $610K |
| Changes in Working Capital: | ||||
| Accounts Receivable | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Accounts Payable | $2.21M | -$346K | $856K | $0 |
| Other Working Capital | $1.29M | -$2.07M | $1.8M | $1.49M |
| Total Working Capital Change | $3.5M | -$2.42M | $2.65M | $1.49M |
| Other Non-Cash Items | $636K | $4.82M | $1.32M | $5.3M |
| Net Cash from Operating | -$87.47M | -$64.83M | -$27.18M | -$3.24M |
| Investing Activities | ||||
| Capital Expenditures | -$616K | -$2.4M | -$1.64M | -$284K |
| Acquisitions | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$354.78M | -$380.74M | -$77.22M | $0 |
| Sales of Investments | $167.93M | $209.8M | $0 | $0 |
| Other Investing Activities | $0 | $3.21M | $0 | -$5M |
| Net Cash from Investing | -$187.47M | -$170.14M | -$78.86M | -$5.28M |
| Financing Activities | ||||
| Debt Repaid | - | - | - | -$7.9M |
| Common Stock Issuance | $270.79M | $157.71M | $54K | $31.79M |
| Common Stock Repurchases | -$1K | $0 | -$4K | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $7K | -$134K | $0 |
| Net Cash from Financing | $270.79M | $221.63M | $145.14M | $39.69M |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$4.16M | -$13.34M | $39.09M | $31.16M |
| Supplementary Data | ||||
| Operating Cash Flow | -$87.47M | -$64.83M | -$27.18M | -$3.24M |
| Capital Expenditure | -$616K | -$2.4M | -$1.64M | -$284K |
| Free Cash Flow | -$88.09M | -$67.23M | -$28.82M | -$3.53M |
| Cash at Beginning | $56.91M | $70.25M | $31.16M | $0 |
| Cash at End | $52.75M | $56.91M | $70.25M | $31.16M |